Targeting ischemic penumbra Part II: selective drug delivery using liposome technologies

Liu, Shimin; Levine, Steven R.; Winn, H Richard

doi:10.4172/1939-067x.1000134

Cited by 3 publications

(5 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been confirmed that during ischemia reperfusion, the secondary cerebral damages due to BBB disruption and permeabilization of the vascular endothelial cells permit penetration of nanoliposomes into the ischemic brain . In this experiment, we applied extrusion method to make monodisperse nanoliposomes to enhance penetration of carrier into the brain after I/R induction . We also used DOPE phospholipid in liposome bilayer to involve endosomal escape after the endocytosis where efficient intracellular delivery of CsA is necessary as a peptide .…”

Section: Discussionmentioning

confidence: 96%

“…Among the novel drug delivery systems, nanoliposomes are well known as safe and designable carrier that can be made for efficient delivery of drugs into the brain tissue after ischemia reperfusion . It has been confirmed that during ischemia reperfusion, the secondary cerebral damages due to BBB disruption and permeabilization of the vascular endothelial cells permit penetration of nanoliposomes into the ischemic brain .…”

Section: Discussionmentioning

confidence: 99%

“…Liposomes with unique properties in delivery of protein and peptides can improve deficits in brain targeting . It is evidenced that nanosized liposomes are nontoxic and successful in accumulation of their cargo in brain tissue and reduced effective dose of drug in amelioration of brain injury models . Furthermore, in‐vitro and in‐vivo reports showed that liposomal CsA containing phosphatidylserine (PS) and phosphatidylethanolamine (DOPE) phospholipids dramatically enhanced pharmacologic effects of CsA in experimental models .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Nanoliposome containing cyclosporine A reduced neuroinflammation responses and improved neurological activities in cerebral ischemia/reperfusion in rat

Partoazar

Nasoohi

Rezayat

et al. 2016

Fundam Clin Pharmacol

View full text Add to dashboard Cite

Cyclosporine A (CsA) is known as a neuroprotective agent against cerebral ischemia/reperfusion (I/R) in animal models. However, the significant therapeutic effects of CsA have been observed in high systemic doses or manipulating the blood-brain barrier, resulting in systemic side effects and toxicity. As the liposome nanocarriers have been developed for efficient delivery of peptide and proteins, liposomal CsA (Lipo-CsA) could improve cerebral (I/R) injuries. In this study, the liposomal CsA formulation (CsA at dose of 2.5 mg/kg) was prepared to assess the brain injury outcomes in 90 min middle cerebral artery occlusion (MCAO) stroke model followed by 48 h reperfusion in treating rats. Five minutes after induction of cerebral ischemia in rats, intravenous (iv) administration of Lipo-CsA significantly (P < 0.001) recovered the infarct size, the brain edema, and the neurological activities compared to corresponding control groups following 48 h I/R. In addition, after 48 h cerebral I/R, Lipo-CsA potentially (P < 0.001) inhibited the inflammation responses including MPO activity and tumor necrosis factor-alpha level in comparison to other groups. In conclusion, the results indicate that the low dose of CsA in liposomal formulation is more effective compared to higher dose of free form of CsA in treatment of ischemic brain in rats.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nanoliposome containing cyclosporine A reduced neuroinflammation responses and improved neurological activities in cerebral ischemia/reperfusion in rat

Partoazar

Nasoohi

Rezayat

et al. 2016

Fundam Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…Pimonidazole hydrochloride (HypoxyprobeTM) is a commercially available hypoxia indicator capable of penetrating the blood brain barrier (BBB; Li et al, 2018), which limits the diffusion of hydrophilic molecules but allows diffusion of lipophilic or uncharged small molecules from circulation into the central nervous system. Ischemia with and without reperfusion disrupts the BBB, causing edema, hemorrhagic transformation, and exacerbates the brain injury (Liu et al, 2011). The oxidative metabolism of pimonidazole is regulated by NADH and NADPH redox states.…”

Section: Introductionmentioning

confidence: 99%

Expression of miR-200c corresponds with increased reactive oxygen species and hypoxia markers after transient focal ischemia in mice

Arvola

Griffiths

Rao

et al. 2021

Neurochemistry International

View full text Add to dashboard Cite

“…Unlike the microvasculature in the periphery, brain endothelial cells (BECs) are interconnected by tight junctions (TJs) that seal spaces between endothelial cells [6]. TJs form a physical barrier for paracellular transport and limit brain penetration of large hydrophilic macromolecules that would otherwise readily cross the endothelial cells ( Figure 1) [7].…”

Section: Challenges Of Cns Drug Delivery: the Bbb Obstaclementioning

confidence: 99%

Selective drug delivery approaches to lesioned brain through blood brain barrier disruption

Al-Ahmady

2018

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

The development of therapeutics for central nervous system (CNS) disorders is still considered a challenging area in drug development due to insufficient translocation through the blood-brain barrier (BBB). Under normal conditions, BBB restrict the penetration of more than 98% of blood-borne molecules including drugs to the CNS. However, recent research findings have proven that the nature of the BBB is altered in several neurological conditions. This complexity encourages revisiting drug delivery strategies to the CNS as this can give a wide range of opportunities for CNS drug development. Areas covered: This review focuses on nanotechnology-based drug delivery platforms designed for selective recruitment into the lesioned brain by taking advantages of BBB disruption that is associated with certain neurological conditions. Expert opinion: Current CNS therapeutic strategies do not fully address the pathophysiological adaptation of BBB in their design. The lack of selective delivery to the brain lesions has been the culprit behind the failure of many CNS therapeutics. This highlighted the need for smart designs of advanced drug delivery systems that take advantage of BBB structural changes in CNS diseases. Recently, promising examples have been reported in this area, however, more work is still required beyond the preclinical testing.

show abstract

Targeting ischemic penumbra Part II: selective drug delivery using liposome technologies

Cited by 3 publications

References 47 publications

Nanoliposome containing cyclosporine A reduced neuroinflammation responses and improved neurological activities in cerebral ischemia/reperfusion in rat

Nanoliposome containing cyclosporine A reduced neuroinflammation responses and improved neurological activities in cerebral ischemia/reperfusion in rat

Expression of miR-200c corresponds with increased reactive oxygen species and hypoxia markers after transient focal ischemia in mice

Selective drug delivery approaches to lesioned brain through blood brain barrier disruption

Contact Info

Product

Resources

About